Join our next webinar on the Madrid Protocol

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Join our next webinar on the Madrid Protocol

Our next Managing IP webinar is taking place this Thursday and is titled “Mad about Madrid: How to leverage Madrid Protocol to your best advantage”

I’m delighted to say we have secured some great speakers for this webinar, which is the latest in a series we have been hosting in association with Lecorpio.

Fran Jagla

The webinar takes place this Thursday September 24 at 6pm (London), 1pm (New York), 10 am (West Coast).

Joining me for the discussion will be:

  • Fran Jagla (right), a shareholder of Lane Powell, who has spent much of her career in house at companies such as Abbott Laboratories and Microsoft and has extensive experience in name development, clearance filing, registration, maintenance and enforcement of trade marks and copyrights.

  • Jeff Epstein (below left), a partner of Cowan Liebowitz & Latman, who practises in trade mark and copyright law, including before the TTAB and advises many multinational companies on their worldwide IP protection strategies.

  • Mark Bullard (below right), who will be familiar to those of you who have listened to previous webinars in this series and is vice president of product management at Lecorpio.

Jeff Epstein

The discussion, which promises to be open and frank, will focus on the pros and cons of the Madrid System, particularly as it grows in the Americas (Mexico and Colombia have recently joined, and Canada is expected to do so soon).

It is particularly aimed at trade mark practitioners in the US who use, or are considering using, Madrid for their trade mark portfolios. But we anticipate that it will also be of interest to practitioners in other countries.

We plan to debate advantages such as the cost, speed and simplicity of the system as well as challenges related to the specification of goods, bona fide intent to use, limitations and central attack.

Mark Bullard

We will also be discussion the experience so far in the US, Mexico, Colombia, Cuba and Antigua & Barbuda, as well as the possibility of Brazil and Canada joining, and what impact that would have.

Finally, we will look at some specific issues in the pharmaceutical, fashion and motion picture industries.

As with all our webinars, there will also be an opportunity for the audience to ask questions of the panellists.

The webinar is free to attend: just register here and join us on Thursday.

more from across site and SHARED ros bottom lb

More from across our site

Partners Alex Wilson and Andreas Kramer say bigger law firm rivals don’t necessarily gain by having a wider jurisdictional reach
VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Academic Eden Sarid joins us during Pride Month to discuss queer expression and IP law, Patagonia v Pattie Gonia, and how queer and AI-generated creations both pose novelty concerns
Patent attorney Michael Henson joins the firm to lead its freshly launched blockchain and digital assets practice
A dispute over mammogram technology, and a development in the case between GSK and Moderna were also among the top talking points in recent weeks
With rankings for Western Europe set to be published on June 25, we sat down with our research lead to find out what practitioners and law firms can expect
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Gift this article